Boltz Raises $110M Series A to Build the SaaS Engine for AI Drug Discovery

As the biotech industry shifts from manual lab work to computational design, AI biology startup Boltz has raised a $110 million Series A to prove that software—not just proprietary drug pipelines—can be a venture-scale business.
The pharmaceutical industry has long relied on massive, capital-intensive drug pipelines to justify venture investments. But as artificial intelligence proves capable of predicting complex molecular interactions, a new class of startups is emerging to sell the underlying computational infrastructure as a service, rather than developing their own therapeutics.
AI bio startup Boltz, which launched from stealth earlier this year, has secured a $110 million Series A led by Bessemer Venture Partners. Founded by former MIT researchers Gabriele Corso, Saro Passaro, and Jeremy Wohlwend, the company initially gained traction by open-sourcing biomolecular foundation models like Boltz-1 and Boltz-2. The fresh capital will fuel the expansion of its proprietary commercial platform, Boltz Lab, which allows researchers to design proteins and small molecules using natural language workflows.
Unlike competitors such as Google's Isomorphic Labs, which uses its AI to develop its own proprietary drugs, Boltz operates strictly as a software provider. Its platform integrates generative diffusion models with specialized architectures to predict binding affinities and optimize molecules for "developability"—ensuring a designed protein can actually be manufactured and remain stable in a cellular environment. The company claims its optimized infrastructure runs significantly faster than self-hosted open-source alternatives.
The massive funding round signals a strategic shift in how venture capital views the intersection of AI and biology. With six of the top 20 global drugmakers already using Boltz Lab, the startup is betting that democratizing access to frontier AI models will ultimately create a broader industry impact than hoarding the technology for internal drug development.
INTELLIGENCE BRIEF
WHY IT MATTERS
Boltz is proving that pure-play software can be a venture-scale business in biotech, challenging the traditional model where AI companies must develop their own drugs to justify high valuations.
WHO IS INVOLVED
Gabriele Corso (CEO), Saro Passaro (Co-founder), Jeremy Wohlwend (CTO), Bessemer Venture Partners
MARKET IMPACT
By democratizing access to frontier biomolecular models, Boltz enables smaller biotechs and academic labs to compete with massive pharmaceutical R&D budgets.
This story was drafted with AI assistance and reviewed by TurkSpark editors before publication. Facts, figures, and names may be inaccurate — verify important details independently.


